NCT05817240View on ClinicalTrials.gov

A Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

May 3, 2023

Primary Completion Date

June 11, 2023

Study Completion Date

June 21, 2023

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

taladegib

100 mg per tablet, dosed once daily

DRUG

nintedanib

100 mg per capsule, dosed once daily

Trial Locations (1)

5000

Research Site, Adelaide

Sponsors
All Listed Sponsors
lead

Endeavor Biomedicines, Inc.

INDUSTRY

NCT05817240 - A Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects | Biotech Hunter | Biotech Hunter